RxDoctor Payments Data

George Yesenosky, MD

Clinical Cardiac Electrophysiology · Philadelphia, PANPI 1265408470

Payments from drug & device makers

$74,342in general payments, 2019–2025

Across 459 payments — averaging $161.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Impulse Dynamics (USA) Inc.$32K
  • Boston Scientific$25K
  • Abbott$5K
  • Medtronic$4K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$3K
  • Atricure, Inc.$1K
  • plus $5K from 29 others

What the payments were for

  • Consulting fees$28,25638%
  • Speaking & faculty fees$23,00031%
  • Travel & lodging$8,23511%
  • Food & beverage$14,85120%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$74,342 in reported general payments places this provider in the 70th percentile of 201 clinical cardiac electrophysiology providers in Pennsylvania.

See all clinical cardiac electrophysiology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$173,596
Medicare patients
1,041
Services billed
2,923

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban191$202,755
XareltoRivaroxaban69$78,476
Repatha SureclickEvolocumab44$50,209
EntrestoSacubitril/Valsartan25$42,553
VascepaIcosapent Ethyl13$8,923
JardianceEmpagliflozin11$7,636
Atorvastatin Calcium251$4,393
Metoprolol Succinate244$4,084
Rosuvastatin Calcium73$2,342
Diltiazem 24hr Er (Cd)Diltiazem Hcl32$2,199
Ezetimibe66$1,498
Amiodarone Hcl91$1,441
Losartan Potassium96$1,391
Amlodipine Besylate93$1,039
Pantoprazole Sodium24$956

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$306$202,755191 claims
Johnson & JohnsonXarelto$257$78,47669 claims
NovartisEntresto$502$42,55325 claims
Boehringer IngelheimJardiance$340$7,63611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 201 clinical cardiac electrophysiology providers in Pennsylvania.

Other clinical cardiac electrophysiology in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →